Sorafenib and venetoclax for MRD-positive AML
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests if combining sorafenib and venetoclax can help people with acute myeloid leukemia (AML) who still have minimal residual disease (MRD) after treatment. The goal is to prevent the leukemia from coming back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have acute myeloid leukemia (AML) with minimal residual disease (MRD) left after earlier treatment.
- Your liver and kidneys must work well enough (bilirubin ≤ 35 μmol/L, AST/ALT less than 2 times normal, creatinine ≤ 150 μmol/L).
- Your heart must function normally (ejection fraction ≥ 50%, NYHA class I or II).
- You must be able to perform daily activities with little help (ECOG score 0-2).
- If you could become pregnant, you must have a negative pregnancy test and agree to use birth control during treatment. Men must also use contraception during and for 3 months after treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug combo (tagraxofusp, azacitidine, and venetoclax) for people with acute myeloid leukemia (AML) who have very small amounts of cancer cells still present after initial treatment. The goal is to see if it can clear these leftover cells and prevent the cancer from coming back.
This trial tests whether the combination of venetoclax and azacitidine can clear small amounts of leukemia cells that remain after initial chemotherapy (called measurable residual disease or MRD). It is for people with acute myeloid leukemia who have MRD before a stem cell transplant.
This trial tests two targeted drugs, venetoclax and revumenib, for people with acute myeloid leukemia (AML) that has a specific change in the NPM1, KMT2A, or NUP98 genes and has minimal residual disease (MRD) after treatment. The goal is to see if this combination can clear remaining leukemia cells and improve outcomes.
This trial is for people with acute myeloid leukemia (AML) who are in remission but still have tiny traces of leukemia cells that can be found with sensitive tests (called MRD-positive). The study is testing a new treatment approach to try to get rid of those remaining cells and prevent the cancer from coming back.
This trial tests a combination of venetoclax with liposome chemotherapy (daunorubicin and cytarabine) for adults with acute myeloid leukemia (AML) that is back after treatment or not responding, and for some newly diagnosed cases. It aims to shrink leukemia and help more people achieve remission.
This study is for adults with newly diagnosed acute myeloid leukemia (AML) who will receive the drugs azacitidine and venetoclax as their first treatment. Researchers will monitor tiny amounts of cancer left after treatment (MRD) to see how it affects survival.
Hear when a new Acute Myeloid Leukaemia (AML) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.